Pharmacological activation of p53 triggers anticancer innate immune response through induction of ULBP2.
about
DRAGO (KIAA0247), a new DNA damage-responsive, p53-inducible gene that cooperates with p53 as oncosuppressor. [Corrected]Immune surveillance of unhealthy cells by natural killer cellsImmunomodulatory Function of the Tumor Suppressor p53 in Host Immune Response and the Tumor MicroenvironmentNKG2D and DNAM-1 Ligands: Molecular Targets for NK Cell-Mediated Immunotherapeutic Intervention in Multiple MyelomaIntegrated high-throughput analysis identifies Sp1 as a crucial determinant of p53-mediated apoptosis.Regulation of ligands for the NKG2D activating receptor.Recognition of tumors by the innate immune system and natural killer cells.Wild type p53 reactivation: from lab bench to clinic.Cannabinoid receptor CB1 regulates STAT3 activity and its expression dictates the responsiveness to SR141716 treatment in human glioma patients' cellsGenome-Wide Gene Expression Analysis Identifies the Proto-oncogene Tyrosine-Protein Kinase Src as a Crucial Virulence Determinant of Infectious Laryngotracheitis Virus in Chicken Cells.Immunosurveillance and immunotherapy of tumors by innate immune cells.Tissue-specific expression of p73 C-terminal isoforms in mice.Recent discoveries in the cycling, growing and aging of the p53 fieldHLA class I downregulation is associated with enhanced NK-cell killing of melanoma cells with acquired drug resistance to BRAF inhibitors.p53-dependent chemokine production by senescent tumor cells supports NKG2D-dependent tumor elimination by natural killer cellsCBP/p300 acetyltransferases regulate the expression of NKG2D ligands on tumor cellsProstate cancer and immunoproteome: awakening and reprogramming the guardian angels.Targeting NKG2D in tumor surveillance.Virus-mediated inhibition of natural cytotoxicity receptor recognition.Battle of the midgets: innate microRNA networking.NRF2 and p53: Januses in cancer?Molecular mechanisms of natural killer cell activation in response to cellular stress.The DNA Damage Response: A Common Pathway in the Regulation of NKG2D and DNAM-1 Ligand Expression in Normal, Infected, and Cancer Cells.Advances in NKG2D ligand recognition and responses by NK cells.NKG2D signaling in cancer immunosurveillance.Molecular Bases for the Regulation of NKG2D Ligands in Cancer.New perspective on targeting the tumor suppressor p53 pathway in the tumor microenvironment to enhance the efficacy of immunotherapy.A novel facet of tumor suppression by p53: Induction of tumor immunogenicity.Tumor suppressors control ULBP2, an innate surface ligand of the lymphocyte immune receptor NKG2D.New prospects on the NKG2D/NKG2DL system for oncology.Combined detection of serum UL16-binding protein 2 and macrophage inhibitory cytokine-1 improves early diagnosis and prognostic prediction of pancreatic cancer.p38 MAPK differentially controls NK activating ligands at transcriptional and post-transcriptional level on multiple myeloma cells.Recognition by natural killer cells of N6-isopentenyladenosine-treated human glioma cell lines.NKG2D and Its Ligands: "One for All, All for One".Neuroblastoma Cell Lines Are Refractory to Genotoxic Drug-Mediated Induction of Ligands for NK Cell-Activating Receptors.Tumor-derived CSF-1 induces the NKG2D ligand RAE-1δ on tumor-infiltrating macrophages.New Insights Into the Regulation of Natural-Killer Group 2 Member D (NKG2D) and NKG2D-Ligands: Endoplasmic Reticulum Stress and CEA-Related Cell Adhesion Molecule 1.
P2860
Q24339462-32083D0A-DF7C-458B-B547-FE0022339D26Q27003079-C37262B7-8A48-44B0-9B2C-AC2F96AFA08AQ28071935-A32D4621-52DE-4F74-A6D7-8E41B4FD81E0Q28080823-39E5CEE3-E969-408A-A270-CF8C53CE019AQ34038417-BF29AC15-E185-424D-B768-C788AB9853A0Q34321457-281A777D-5A93-4F1C-8058-B96554CFF28CQ34496462-AFDA3201-B0CA-4610-92A6-25F1BF503C8BQ35146343-1B9D7129-831B-418A-872D-9CEFFC68AFA4Q36021048-550A3E45-10D8-4467-B02D-5F4447621845Q36433936-D5F5892E-6B3D-4B7F-8E34-6444BA386A02Q36471212-D8BD448A-118E-444A-9251-01D98C97D489Q36556362-864C7CFA-E487-4293-82F8-B619E4EBCCEDQ36736358-CFEAD496-00C4-4E54-9A0F-0520960691D6Q36799788-00725A2B-30F3-4FE8-8781-8CE86DD83415Q37194949-1B4DA9D0-BC45-4AB4-A8AD-B3EE6187894FQ37654516-3F9F1475-42C3-45CD-8839-174494041F1CQ38000961-35FC3C1B-DE3D-4C0C-A880-99CF363DAB1EQ38005176-2130EAEF-248C-4A81-9108-637D866E095CQ38006620-A1B0C7EB-38FC-4386-BF0B-0FB82689BF70Q38012336-4CAAEB75-60D7-4253-AD9A-CDF1D72BFDF6Q38061832-14680057-3B61-468E-9A5B-212460895CD1Q38098383-E9F9EADD-8077-4D45-AAF0-3DD0D8FA5CC5Q38178966-2DAFF1E0-5E6B-4D2D-A6A4-6090488313B2Q38180339-CCC9CFA8-158D-46D2-B759-15C2CDBAF047Q38194944-778B0DF0-3A73-4CF0-A541-5B46922ED1ADQ38202957-DBA137C1-A10C-4140-BDE5-BCEA861EB3EFQ38389967-779F62DE-A37C-4E05-9829-5DAD01B51682Q42214198-057F18AC-698D-4F01-B351-3D420F3C68DFQ42214240-CF9A3817-45E1-4AA5-8074-47FB8118447BQ42796257-4AA496C5-F7BE-434E-97C6-AC497D48C746Q42931044-30232DFC-E552-4C98-8B97-4006C7EC6FF1Q45160655-A57F37C9-4156-4033-B834-5E45CE57B042Q47836415-84B3CFED-8D07-4685-BDC5-D7EC5F40D4B9Q54234609-B550D144-D05F-436D-A161-A8B9D33D3AB3Q54941625-DC4A3607-000F-4B75-BDD7-BE2471975872Q54979162-02489B71-49D5-4757-8DE9-6806843CED26Q55450907-BC3EFC12-0F95-4165-A17D-BCB6BF3A0C80
P2860
Pharmacological activation of p53 triggers anticancer innate immune response through induction of ULBP2.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Pharmacological activation of ...... se through induction of ULBP2.
@en
Pharmacological activation of ...... se through induction of ULBP2.
@nl
type
label
Pharmacological activation of ...... se through induction of ULBP2.
@en
Pharmacological activation of ...... se through induction of ULBP2.
@nl
prefLabel
Pharmacological activation of ...... se through induction of ULBP2.
@en
Pharmacological activation of ...... se through induction of ULBP2.
@nl
P2093
P50
P356
P1433
P1476
Pharmacological activation of ...... nse through induction of ULBP2
@en
P2093
Cinzia Garofalo
Clemens Spinnler
Klas Kärre
Tadepally Lakshmikanth
P304
P356
10.4161/CC.10.19.17630
P577
2011-10-01T00:00:00Z